Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00835640 · ClinicalTrials.gov registry record · Phase 1
Fexofenadine Hydrochloride 180 mg Tablets Under Non-Fasting Conditions
A Phase 1 study, sponsored by Teva Pharmaceuticals USA.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00835640: Completed Phase 1 study, sponsored by Teva Pharmaceuticals USA.
NCT00835640 is a Phase 1 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00835640, a Phase 1 study, has completed, sponsored by Teva Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study will compare the relative bioavailability (rate and extent of absorption) of 180 mg Fexofenadine Hydrochloride tablets manufactured for TEVA Pharmaceuticals Industries, Ltd. with that of 180 mg ALLEGRA® Tablets by Aventis Pharmaceuticals, Inc. following a single oral dose (1 x 180 mg tablet) in healthy adult volunteers under fed conditions.
Interventions
- DRUG Fexofenadine 180 mg tablets
- DRUG ALLEGRA® 180 mg tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2002-01 |
| Est. Completion | 2002-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00835640
The ClinicalTrials.gov registry entry for NCT00835640 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Pharmaceuticals USA, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fexofenadine 180 mg tablets is the first listed.
NCT00835640 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00835640 about?
NCT00835640 is a clinical study titled "Fexofenadine Hydrochloride 180 mg Tablets Under Non-Fasting Conditions". This study will compare the relative bioavailability (rate and extent of absorption) of 180 mg Fexofenadine Hydrochloride tablets manufactured for TEVA Pharmaceuticals Industries, Ltd. with that of 180 mg ALLEGRA® Tablets by Aventis Pharmaceuticals, Inc. following a single oral dose (1 x 180 mg tabl...
What is the current status of trial NCT00835640?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2002-01. Estimated completion is 2002-01.
What interventions are being tested in trial NCT00835640?
The interventions under investigation include: Fexofenadine 180 mg tablets (DRUG), ALLEGRA® 180 mg tablets (DRUG).
Who is sponsoring clinical trial NCT00835640?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.